甲状腺功能亢进介导肺癌超进展病例报告
Case Report of Hyperprogression of Lung Cancer Mediated by Hyperthyroidism
DOI: 10.12677/acm.2024.1451668, PDF,   
作者: 陈耿丽*, 蔡兴东, 刘升明#:暨南大学附属第一医院呼吸与危重症医学科,广东 广州;阳一帆:醴陵市中医院老年病科,湖南 株洲
关键词: 甲状腺功能亢进肺癌超进展Hyperthyroidism Lung Cancer Hyperprogression
摘要: 目的:分析甲状腺功能亢进与恶性肿瘤发生发展之间的关系。方法:回顾性分析1例甲状腺功能亢进介导肺癌超进展的患者并复习相关文献。结果:本例老年男性患者,因“咳嗽、咳痰、气促2年余,再发加重3月”入院。既往糖尿病史10年余,甲亢病史5年余,未规律诊治。患者肺部CT平扫不排除肿瘤病变,后经支气管镜活检,结合免疫组化结果,考虑小细胞肺癌。对比其外院2月余前胸部CT结果,考虑肺癌超进展。结论:甲状腺功能亢进可提高肺癌发生发展的易感性。临床医生在诊疗过程中,应加强对甲亢与癌症关联的认识,提高甲亢患者的风险意识,并对癌症患者进行早期识别和明确诊断,以提高患者预后。
Abstract: Objective: To analyze the relationship between hyperthyroidism and the occurrence and development of malignant tumors. Methods: A retrospective analysis was conducted on a case of hyperthyroidism-mediated ultra-progressive lung cancer, along with a review of relevant literature. Result: In this case, an elderly male patient was admitted due to “coughing, expectoration, and dyspnea for over 2 years, exacerbated for 3 months”. He had a medical history of diabetes for more than 10 years and a history of hyperthyroidism for over 5 years, which had not been managed consistently. Pulmonary CT scan suggested possible tumor lesions. Subsequently, bronchoscopic biopsy in combination with immunohistochemical results led to a consideration of small cell lung cancer. Comparing the chest CT findings from over 2 months ago at another hospital, it was concluded that the patient’s lung cancer had undergone ultra-progressive growth. Conclusion: Hyperthyroidism can increase susceptibility to the occurrence and progression of lung cancer. Clinicians should enhance their understanding of the association between hyperthyroidism and cancer during the diagnostic process, raise awareness of the risk among patients with hyperthyroidism, and ensure early recognition and definitive diagnosis of malignancy in these patients, thereby improving patient prognosis.
文章引用:陈耿丽, 阳一帆, 蔡兴东, 刘升明. 甲状腺功能亢进介导肺癌超进展病例报告[J]. 临床医学进展, 2024, 14(5): 2188-2193. https://doi.org/10.12677/acm.2024.1451668

参考文献

[1] Taylor, P.N., Albrecht, D., Scholz, A., et al. (2018) Global Epidemiology of Hyperthyroidism and Hypothyroidism. Nature Reviews. Endocrinology, 14, 301-316. [Google Scholar] [CrossRef] [PubMed]
[2] Roth, G.A., Abate, D., Abate, K.H., et al. (2018) Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 392, 1736-1788. [Google Scholar] [CrossRef
[3] Engholm, G., Ferlay, J., Christensen, N., Bray, F., et al. (2010) NORDCAN—A Nordic Tool for Cancer Information, Planning, Quality Control and Research. Acta Oncologica, 49, 725-736. [Google Scholar] [CrossRef] [PubMed]
[4] Beatson, G.T. (1896) On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases. Transactions. Medico-Chirurgical Society of Edinburgh, 15, 153-179.
[5] Krashin, E., Piekiełko-Witkowska, A., Ellis, M. and Ashur-Fabian, O. (2019) Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. Frontiers in Endocrinology, 10, Article 59. [Google Scholar] [CrossRef] [PubMed]
[6] Davis, F.B., Mousa, S.A., O’Connor, L., Mohamed, S., et al. (2004) Proangiogenic Action of Thyroid Hormone Is Fibroblast Growth Factor-Dependent and Is Initiated at the Cell Surface. Circulation Research, 94, 1500-1506. [Google Scholar] [CrossRef
[7] Bergh, J.J., Lin, H., Lansing, L., Mohamed, S.N., et al. (2005) Integrin αVβ3 Contains a Cell Surface Receptor Site for Thyroid Hormone That Is Linked to Activation of Mitogen-Activated Protein Kinase and Induction of Angiogenesis. Endocrinology, 146, 2864-2871. [Google Scholar] [CrossRef] [PubMed]
[8] Lin, H.Y., Davis, F.B., Gordinier, J.K., et al. (1999) Thyroid Hormone Induces Activation of Mitogen-Activated Protein Kinase in Cultured Cells. American Journal of Physiology, 276, C1014-C1024. [Google Scholar] [CrossRef
[9] Lin, H., Su, Y., Hsieh, M., Lin, S., et al. (2013) Nuclear Monomeric Integrin αv in Cancer Cells Is a Coactivator Regulated by Thyroid Hormone. The FASEB Journal, 27, 3209-3216. [Google Scholar] [CrossRef] [PubMed]
[10] Yeh, N., Chou, C., Weng, S., Yang, C., et al. (2013) Hyperthyroidism and Thyroid Cancer Risk: A Population-Based Cohort Study. Experimental and Clinical Endocrinology & Diabetes, 121, 402-406. [Google Scholar] [CrossRef] [PubMed]
[11] Hellevik, A.I., Asvold, B.O., Bjøro, T., Romundstad, P.R., et al. (2009) Thyroid Function and Cancer Risk: A Prospective Population Study. Cancer Epidemiology, Biomarkers & Prevention, 18, 570-574. [Google Scholar] [CrossRef
[12] Hercbergs, A.H., Ashur-Fabian, O. and Garfield, D. (2010) Thyroid Hormones and Cancer: Clinical Studies of Hypothyroidism in Oncology. Current Opinion in Endocrinology, Diabetes, and Obesity, 17, 432-436. [Google Scholar] [CrossRef
[13] Cristofanilli, M., Yamamura, Y., Kau, S., Bevers, T., et al. (2005) Thyroid Hormone and Breast Carcinoma. Primary Hypothyroidism Is Associated with a Reduced Incidence of Primary Breast Carcinoma. Cancer, 103, 1122-1128. [Google Scholar] [CrossRef] [PubMed]
[14] Backwinkel, K. and Jackson, A.S. (1964) Some Features of Breast Cancer and Thyroid Deficiency. Report of 280 Cases. Cancer, 17, 1174-1176. [Google Scholar] [CrossRef
[15] Hercbergs, A., Mason, J., Reddy, C. and Elson, P. (2004) Thyroid Hormones and Lung Cancer: Primary Hypothyroidism Is Prognostically Significant for Survival in Lung Cancer. Cancer Research, 64, Article 1024.
[16] Moeller, L.C. and Führer, D. (2013) Thyroid Hormone, Thyroid Hormone Receptors, and Cancer: A Clinical Perspective. Endocrine-Related Cancer, 20, R19-R29. [Google Scholar] [CrossRef
[17] Cheng, S., Leonard, J.L. and Davis, P.J. (2010) Molecular Aspects of Thyroid Hormone Actions. Endocrine Reviews, 31, 139-170. [Google Scholar] [CrossRef] [PubMed]
[18] Yalcin, M., Dyskin, E., Lansing, L., Bharali, D.J., et al. (2010) Tetraiodothyroacetic Acid (Tetrac) and Nanoparticulate Tetrac Arrest Growth of Medullary Carcinoma of the Thyroid. The Journal of Clinical Endocrinology and Metabolism, 95, 1972-1980. [Google Scholar] [CrossRef] [PubMed]
[19] De Berardinis, R.J. and Chandel, N.S. (2020) We Need to Talk About the Warburg Effect. Nature Metabolism, 2, 127-129. [Google Scholar] [CrossRef] [PubMed]
[20] Ghergurovich, J.M., Lang, J.D., Levin, M.K., Briones, N., et al. (2021) Local Production of Lactate, Ribose Phosphate, and Amino Acids by Human Triple-Negative Breast Cancer. Med, 2, 736-754.E6. [Google Scholar] [CrossRef] [PubMed]
[21] Martínez-Reyes, I. and Chandel, N.S. (2021) Cancer Metabolism: Looking Forward. Nature Reviews. Cancer, 21, 669-680. [Google Scholar] [CrossRef] [PubMed]
[22] Surks, M.I., Ortiz, E., Daniels, G.H., Sawin, C.T., et al. (2004) Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA, 291, 228-238. [Google Scholar] [CrossRef] [PubMed]
[23] Hartmann, K. (2015) Thyroid Disorders in the Oncology Patient. Journal of the Advanced Practitioner in Oncology, 6, 99-106. [Google Scholar] [CrossRef] [PubMed]